11:06 AM EST, 02/05/2025 (MT Newswires) -- Annovis Bio ( ANVS ) said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.

The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.

The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.

The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.

Shares of Annovis were down 1.4% in recent trading.

Price: 3.10, Change: -0.04, Percent Change: -1.43